Thymic-derived tolerizing dendritic cells are upregulated in the spleen upon treatment with intravenous immunoglobulin in a murine model of immune thrombocytopenia. (4th July 2017)

• Record Type: Journal Article
• Authors: Kapur, Rick; Aslam, Rukhsana; Kim, Michael; Guo, Li; Ni, Heyu; Segel, George B.; Semple, John W.
• Is Part Of: Platelets. Volume 28:Number 5(2017)
• Page Start: 521
• Page End: 524
• Publication Date: 2017-07-04
• Subjects: IVIg -- Dendritic cells -- immune thrombocytopenia; Blood platelets -- Periodicals; Blood Platelets -- Periodicals; 615.39
• DOI: 10.1080/09537104.2016.1246718
• Languages: English
• ISSNs: 0953-7104

Abstract

Abstract: Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by low platelet counts. First-line treatment includes intravenous immunoglobulin (IVIg), however, its working mechanism remains incompletely understood. We investigated splenic and thymic dendritic cell (DC) subsets upon IVIg treatment in a well-characterized active murine model of ITP. During active disease, there was a significant peripheral deficiency of splenic tolerizing SIRPα+ DCs which could be rescued by IVIg therapy, increasing platelet counts. These splenic tolerizing DC changes were associated with an abrogation of the thymic-retention of tolerizing DCs, suggesting that IVIg may raise platelet counts in ITP by modulating peripheral numbers of tolerizing DCs.